Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Live (vaccines) from New York

Bone Marrow Transplantation volume 48, pages 749–754 (2013)Cite this article

Subjects

Abstract

Over 40 000 hematopoietic cell transplantations (HCT) are performed worldwide each year, increasing the number of transplant survivors returning to school, the work place and overseas travel. Outbreaks of measles and mumps in immunocompetent individuals and the increased morbidity associated with primary varicella and shingles in older individuals highlight the need for effective vaccination of these vulnerable patients. In current post-HCT vaccination guidelines, only the measles, mumps and rubella vaccine (MMR) and the live-attenuated varicella vaccine (LAVV) designed to prevent primary varicella in varicella zoster seronegative individuals are permissible post HCT and only in select patient groups. All other vaccines, including the shingles vaccines, are contraindicated post HCT. Current data, primarily in pediatric HCT recipients, demonstrate a 60–70% response following a single MMR or LAVV. A two-dose schedule increases the seroconversion rate following these vaccines. This review will highlight published studies on the immunogenicity of MMR and the LAVV, areas in which data on these vaccines are lacking, the criteria for their use in patients transplanted at our center and potential studies to answer questions posed by the growing number of transplant survivors and their physicians on how to safely administer live-attenuated viral vaccines.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Small TN . Vaccination of hematopoietic cell transplant recipients. In: Appelbaum F, Forman S, Blume KG, Thomas ED, (eds). Hematopoietic Cell Transplantation 108, 4th edn. Blackwell Science: Malden, MA 2009, pp 1664–1670.

    Chapter  Google Scholar 

  2. Small TN, Cowan MJ . Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases. Expert Rev Clin Immunol 2011; 7: 193–203.

    Article  CAS  PubMed  Google Scholar 

  3. Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009; 44: 521–526.

    Article  CAS  PubMed  Google Scholar 

  4. Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159: 610–615.

    Article  CAS  PubMed  Google Scholar 

  5. Pauksen K, Linde A, Ljungman P, Bolme P, Lönnerholm G, Oberg G et al. Specific T and B cell immunity to measles after allogeneic and autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16: 807–813.

    CAS  PubMed  Google Scholar 

  6. King SM, Saunders EF, Petric M, Gold R . Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 633–636.

    CAS  PubMed  Google Scholar 

  7. Pauksen K, Duraj V, Ljungman P, Sjölin J, Oberg G, Lönnerholm G et al. Immunity to and immunization against measles, rubella, and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant 1992; 9: 427–432.

    CAS  PubMed  Google Scholar 

  8. Ljungman P, Lewensohn-Fuchs I, Hammarström V, Aschan J . Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood 1994; 84: 657–663.

    CAS  PubMed  Google Scholar 

  9. Ljungman P, Aschan J, Barkholt L, Broliden PA, Gustafsson B, Lewensohn-Fuchs I et al. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant 2004; 34: 589–593.

    Article  CAS  PubMed  Google Scholar 

  10. Ljungman P, Cordonnier C, De Bock R, Einsele H, Engelhard D, Grundy J et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from infectious disease working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1995; 15: 455–460.

    CAS  PubMed  Google Scholar 

  11. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000; 49: 1–128.

    Google Scholar 

  12. Ljungman P, Engelhard D, de la Cámara R, Einsele H, Locasciulli A, Martino R et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35: 737–746.

    Article  CAS  PubMed  Google Scholar 

  13. Shaw P, Bleakley M, Burgess M . Safety of early immunization against measles/mumps/rubella after bone marrow transplantation. Blood 2002; 99: 3486.

    Article  CAS  PubMed  Google Scholar 

  14. Machado C, de Souza V, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS . Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant 2005; 35: 787–791.

    Article  CAS  PubMed  Google Scholar 

  15. Center for Disease Control and Prevention. Update: mumps outbreak—New York and New Jersey, June 2009–January 2010. MMWR Morb Mortal Wkly Rep 2010; 59: 125–129.

    Google Scholar 

  16. Center for Disease Control and Prevention. Measles—United States, 2011. MMWR Morb Mortal Wkly Rep 2011; 61: 253–257.

    Google Scholar 

  17. Mulholland EK, Griffiths UK, Biellik R . Measles in the 21st century. N Engl J Med 2012; 366: 1755–1757.

    Article  CAS  PubMed  Google Scholar 

  18. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD et al. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271–2284.

    Article  CAS  PubMed  Google Scholar 

  19. Mustafa MM, Weitman SD, Winick NJ, Bellini WJ, Timmons CF, Siegel JD . Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavarin and review of literature. Clin Infect Dis 1993; 16: 654–660.

    Article  CAS  PubMed  Google Scholar 

  20. Nakano T, Shimono Y, Sugigayma K, Nishihara H, Higashigawa M, Komada Y et al. Clinical features of measles in immunocompromised children. Acta Paediatr Jpn 1996; 38: 212–217.

    Article  CAS  PubMed  Google Scholar 

  21. Machado C, Goncalves F, Pannuti C, Dulley FL, de Souza VA . Measles in bone marrow transplant recipients during an outbreak in São Paulo, Brazil. Blood 2002; 99: 83–87.

    Article  CAS  PubMed  Google Scholar 

  22. Patel SR, Ortin M, Cohen BJ, Borrow R, Irving D, Sheldon J et al. Revaccination with measles, tetanus, poliovirus, haemophilus influenzae type b, meningococcus c, and pneumococcus vaccines in children after hematopoietic stem cell transplantation. CID 2007; 44: 625–634.

    Article  CAS  Google Scholar 

  23. Inaba H, Hartford CM, Pei D, Posner MJ, Yang J, Hayden RT et al. Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2011; 156: 109–117.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Small TN, Papadopoulos EB, Boulad F, Kernan NA, Ford R, Taylor J et al. Vaccine responses following unmodified or T cell depleted unrelated and mismatched Related HCT. ASH Annual Meeting 2004; 104: 2226.

    Google Scholar 

  25. Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 2008; 10: 90–98.

    Article  CAS  PubMed  Google Scholar 

  26. Onozawa M, Hashino S, Haseyama Y, Hirayama Y, Iizuka S, Ishida T et al. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol Blood Marrrow Transplant 2009; 15: 724–729.

    Article  Google Scholar 

  27. Tunbridge AJ, Breuer J, Jeffery KJ . British Infection Society. Chickenpox in adults. J Infect 2008; 57: 95–102.

    Article  CAS  PubMed  Google Scholar 

  28. Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000; 6: 44–49.

    Article  CAS  PubMed  Google Scholar 

  29. Thomson KJ, Hart DP, Banerjee L, Ward KN, Peggs KS, Mackinnon S . The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35: 1065–1069.

    Article  CAS  PubMed  Google Scholar 

  30. Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007; 110: 3071–3077.

    Article  CAS  PubMed  Google Scholar 

  31. Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P . Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 381–383.

    Article  CAS  PubMed  Google Scholar 

  32. Ljungman P, Wang FZ, Nilsson C, Solheim V, Linde A . Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care Cancer 2003; 11: 739–741.

    Article  CAS  PubMed  Google Scholar 

  33. Kussmaul SC, Horn BN, Dvorak CC, Abramovitz L, Cowan MJ, Weintrub PS . Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant 2010; 45: 1602–1606.

    Article  CAS  PubMed  Google Scholar 

  34. Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A, Kobos R et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 2011; 17: 1708–1713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Marin M, Güris D, Chaves SS, Schmid S, Seward JF, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1–40.

    PubMed  Google Scholar 

  36. Curtis KK, Connolly MK, Northfelt DW . Live attenuated varicella zoster vaccination of an immunocompromised patient. J Gen Intern Med 2008; 23: 648–649.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. New Eng J Med 2002; 347: 26–34.

    Article  PubMed  Google Scholar 

  38. King J, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr. Infect. Dis J 2001; 20: 1124–1131.

    Google Scholar 

  39. Carr S, Allison K, Van De Velde LA, Zhang K, English EY, Iverson A et al. Safety and Immunogenicity of live attenuated and inactivated Influenza Vaccines in children with cancer. J Infect. Dis 2011; 204: 1475–1482.

    CAS  Google Scholar 

  40. Halasa N, Englund JA, Nachman S, Weinberg GA, Huber VC, Allison K et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 2011; 29: 4110–4115.

    Article  CAS  PubMed  Google Scholar 

  41. Center for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among Infants and children: Recommendations of the Advisory Committee on Immunization practices—United States. MMWR Morb Mortal Wkly Rep 2009; 58: 1–25.

    Google Scholar 

  42. Liakopoulou E, Mutton K, Carrington D, Robinson S, Steward CG, Goulden NJ et al. Rotavirus as a significant cause of prolonged diarrhoeal illness and morbidity following allogeneic bone marrow transplantation. Bone Marrow Transplant 2005; 36: 691–694.

    Article  CAS  PubMed  Google Scholar 

  43. Patel NC, Hertel PM, Estes MK, de la Morena M, Petru AM, Noroski LM et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362: 314–319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kitchener S . Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004; 22: 2103–2105.

    Article  CAS  PubMed  Google Scholar 

  45. Gowda R, Cartwright K, Bremner JAG . Yellow fever vaccine: a successful vaccination of an immunocompromised patient. Eur J Haematol 2004; 72: 299–301.

    Article  CAS  PubMed  Google Scholar 

  46. Yax JA, Farnon EC, Cary Engleberg N . Successful immunization of an allogeneic bone marrow transplant recipient with live, attenuated yellow Fever vaccine. J Travel Med 2009; 16: 365–367.

    Article  PubMed  Google Scholar 

  47. Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, Childs BH et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999; 93: 467–480.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics and Clinical Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    C J Forlenza & T N Small

Authors
  1. C J Forlenza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T N Small
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T N Small.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forlenza, C., Small, T. Live (vaccines) from New York. Bone Marrow Transplant 48, 749–754 (2013). https://doi.org/10.1038/bmt.2012.141

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.141

Keywords

This article is cited by

Search

Advanced search

Quick links